用户名:  密码:   
栏目导航 — 美国华裔教授专家网科技动向生物医学
关键字  范围   
2019/6/10 16:57:13 | 浏览:1424 | 评论:0


The global pharmaceutical industry reached unprecedented heights in 2018, being estimated at an astounding $1.11 trillion. By 2020, this figure is set to rise to $1.43 trillion. With rising pressure to develop drugs to meet ever increasing global demand, pharmaceutical companies continue to work tirelessly to bring the most innovative and cutting-edge treatments to patients.


Being a research-driven industry, approximately $150 billion is spent by pharmaceutical companies every year on research and development projects. Out of thousands of compounds, only a small percentage gain regulatory approval to be used by patients to treat disease and improve quality of life. However, in 2018, a record number of novel drugs developed by pharmaceutical companies across the globe were approved by various regulatory bodies. A large proportion were approved by the US regulatory body, the FDA, which approved 55 novel drugs and smashed its record for generic approvals(781 up from 763 in 2017).


Although the USA’s market share of the global pharmaceutical industry is worth over $341.1 billion, the Chinese, South East Asian, Eastern European and South American markets are beginning to emerge. For example, the Chinese market is rich with preclinical and early-phase drugs, and is a growing nucleus of biotech activity. The next few years will see global growth thanks to the increasing wealth worldwide, as well as increasing demand to maintain high levels of innovation to combat unmet medical need.


ProClinical has ranked the leading pharmaceutical companies according to 2018 revenue from their pharmaceutical segment only. Below is a list of the top 10 biggest pharma companies in the world in 2019:



10. Bristol-Myers Squibb(BMS)US $22.6 billion

布里斯托尔-迈尔斯·施贵宝Bristol-Myers Squibb(BMS)226亿美元

A new entry into the top 10 pharma list is Bristol-Myers Squibb, a leading American pharmaceutical company headquartered in New York City. BMS specialises in four key therapy areas:oncology, cardiovascular, immunoscience and fibrosis. The company's strong growth in 2018 can be in part attributed to continued success of leading drugs Opdivo(cancer)and Eliquis(a blood thinner). BMS' success is likely to be further boosted following the company's planned acquisiton of Celgene - an innovative oncology biotech - in early 2019. This strategic acquisition will help position BMS as a leading biopharma player thanks to Celgene's robust pipeline.



9. GlaxoSmithKline(GSK)US $23 billion


A staple candidate in the top 10 pharma list year on year, GlaxoSmithKline(GSK)is a leading British pharmaceutical company that always boasts a strong pipeline of innovative drugs. The company specialises in a broad range of therapy areas but is particularly successful in the fields of HIV/AIDS, respiratory and vaccines. The company enjoyed 2% revenue growth compared with 2017 figures, with sales being boosted by GSK’s best-selling HIV drugs Trivicay and Triumeq, the Ellipta inhaler for asthma and COPD and Nucala, another successful asthma treatment. Last year GSK saw the key approval of Shingrix, developed to treat the shingles virus, which was very successful in 2018 as expected, with sales reaching £784 million. In general, growth was slightly offset by steep generic competition in 2018 for various GSK drugs like Seretide, Epizixom and Avodart.



8. Amgen US $23.7 billion

安进 237亿美元

Amgen is an American biopharmaceutical company headquartered in California that specialises in developing novel human therapeutics, with a focus on cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The company is steadily becoming a permanent fixture on this top 10 list. This change is in part due to the success of various Amgen products, including Repatha(72% increase yoy), BLINCYTO®(31% increase yoy)and Prolia®(16% increase yoy). In early 2019, Amgen was voted one of Fortune Magazine’s Most Admired Companies in the pharmaceutical industry and was listed number 5 on Fast Company's 2019 Most Innovative companies.

安进是一家总部设在加利福尼亚州的美国生物制药公司,专门开发新型人体疗法,重点研究心血管疾病、肿瘤学、骨健康、神经科学、肾病和炎症。该公司正稳步成为排名前十位的常客。这一变化部分是由于各种安进产品的成功,包括Repatha(72%增加YY),BLINCYTO?(31%增加YY)和Prolia?(16%增加YY)。2019年初,安进被“财富”杂志评选为制药行业最受尊敬的公司之一,并在FastCompany 2019年最具创新能力的公司中名列第五。


7. AbbVie US $32.8 billion

艾伯维 AbbVie 328亿美元

Research-driven American biopharma AbbVie has maintained its position on this list, with an impressive increase of 16.2% compared with 2017 pharma revenue statistics. AbbVie has recently announced that upadacitinib, one of their most anticipated drugs in development that will be used to treat moderate to severe atopic dermatitis, has been granted breakthrough therapy designation by the FDA. This is just one of the many promising pipelined drugs in AbbVie’s varied portfolio which spans multiple therapy areas, including dermatology, oncology, neurology and gastroenterology. Boosting revenue is AbbVie’s top selling drugs Humira, the current bestselling drug in the world and Imbruvica, one of today’s leading cancer drugs.

研究驱动的美国生物Pharma abbvie一直保持其在这份名单上的地位,与2017年制药收入统计数字相比,增长了16.2%。AbbVie最近宣布,upadacitinib,他们最期待开发的药物之一,将用于治疗中至重度特应性皮炎,已获得美国食品和药物管理局的突破性治疗指定。这只是AbbVie的多种药物组合中许多有希望的流水线药物之一,它跨越多种治疗领域,包括皮肤病学、肿瘤学、神经学和胃肠病学。增加收入是AbbVie最畅销的药物Humira(目前世界上最畅销的药物)和Imbruvica(当今领先的癌症药物之一)。


6. Novartis US $34.9 billion


One of the leading pharmaceutical companies in Switzerland, Novartis comfortably makes the top 10 pharma list for 2019. The company focuses on a wide range of disease areas including oncology, immunology/dermatology, neuroscience and respiratory. The company's revenue grew by 5.8% compared with 2017 figures despite a few top selling drugs facing generic competition in major markets, such as as oncology success Gleevec, and blood pressure drugs Diovan and Exforge. To combat these losses, Novartis spent 18% of their overall 2017 revenue on research & development in 2018. Currently, Novartis' best selling drugs are Gilenya, for multiple sclerosis, and Lucentis, for patients suffering from eye-degenerative diseases.



5. Merck & Co US $37.7 billion


American pharmaceutical company Merck takes a spot as one of the top 5 pharmaceutical companies in the world in 2018. Merck is known as MSD outside of North America. The company develops drugs, vaccines and biologics in many areas including cardiovascular, oncology, endocrinology and infectious disease. The company saw an impressive 12.2% revenue growth since 2017 with sales boosted by the continued success of Merck’s bestselling drugs:cancer immunotherapy Keytruda, HPV vaccine Gardasil and diabetes pill Januvia.



4. Sanofi US $39.3 billion


4th on the top 10 pharma list is French pharmaceutical company, Sanofi. The company saw 7.1%% revenue growth within its pharmaceutical sector, which contributes a substantial percentage of the company’s total revenue. Over 25% of this revenue came from Sanofi’s three best selling drugs, Lantus, an insulin injection for diabetes, Lovenox, an anticoagulant to prevent blood clots, and Aubagio, the one-daily pill to treat a form of multiple sclerosis.



3. Johnson & Johnson US $40.7 billion


In the top 3 pharmaceutical companies in the world is Johnson & Johnson, a company that was established over 130 years ago and has become a staple household name thanks to popular consumer goods like Aveeno, Neutrogena and Listerine. The notable 12.1% growth can be in part attributed to its acquisition of biopharmaceutical company Actelion in 2017, which contributed a 3.4% increase in 2018 thanks to its pulmonary arterial hypertension portfolio. Other drivers of growth included best-selling drugs Stelara, Darzalex and Zytiga.



2. Roche US $45.6 billion


Swiss pharmaceutical company, Roche, is the 2nd biggest pharmaceutical company in the world for 2019, and employs 94,442 people worldwide. The company develops innovative drugs and devices in a number of key indications, such as oncology, immunology, infectious diseases and neuroscience. Annual growth from the pharmaceutical segment was 2.7% and revenue from the top 3 products contributed over 40% of Roche’s total revenue in 2018($57.2 bn). Roche’s best-selling drugs also happen to be in the world’s top cancer drugs:Herceptin, Avastin and Rituxan. Roche's CEO, Severan Schwan reported that new medicines in accounted for 90% of the company's growth in 2018, particularly the launch of Ocrevus, said to be the most successful in Roche's history.

瑞士制药公司罗氏(Roche)是2019年全球第二大制药公司,在全球拥有94,442名员工。该公司在肿瘤学、免疫学、传染病和神经科学等许多关键适应症中开发创新药物和设备。制药行业的年增长率为2.7%,前3大产品的收入占罗氏2018年总收入的40%以上(572亿美元)。罗氏最畅销的药物也恰好是世界顶级癌症药物之一:赫赛汀、阿瓦斯丁和利图克。罗氏首席执行官西弗兰·施万(Severan Schwan)报告称,2018年,新药占公司增长的90%,尤其是Ocrevus的推出,据说是罗氏历史上最成功的一次。


1. Pfizer US $53.7 billion


The world’s largest pharmaceutical company is multinational pharma giant Pfizer, headquartered in Connecticut, USA. The research-based company has a varied portfolio that spans many therapy areas, including immunology, oncology, neurosciences and rare diseases. Despite modest revenue growth, Pfizer had a very successful year in 2018. The company received several FDA approvals, particularly in oncology, and many of its best-selling products have many years of patent protection remaining. There was particular growth with some of Pfizer’s key products, including Ibrance, Eliquis and Xeljanz.


超级大脑!伊利诺伊大学厄巴纳·香槟分校科学家用8万鼠脑细胞造活体计算机 2023-03-21 [23]
这些前沿的AI医学技术 正在西达赛奈医学中心(Cedars-Sinai)“上岗” 2023-03-21 [23]
UCSD 新药可延缓“渐冻症”导致的瘫痪 2023-03-21 [45]
BMJ子刊:咖啡或茶抑制体脂量,降低糖尿病、肥胖的风险 2023-03-18 [179]
Nature:哈佛大学开发出通用型癌症疫苗,或可治疗多种癌症 2023-03-07 [233]
《英国运动医学杂志》:UniSA大规模研究发现 运动是抑郁症第一疗法 2023-03-07 [165]
斯坦福大学运用“指导免疫细胞识别癌细胞特”的方式 开发白血病疫苗 2023-03-07 [186]
美国神经学会:全球失智症将增至1.5亿 研究证明7种生活可预防 2023-03-07 [268]
工程化T细胞的最新进展:癌症、自身免疫性疾病、疤痕逆转 2023-03-07 [179]
肉瘤 一般人不了解的癌症 2023-02-28 [275]
:中国336个国家重点实验室布局 :中澳政府联合出手打击洗钱和逃税漏税 大量中国居民海外账户遭冻结 :摄影师苏唐诗与寂寞百年的故宫对话6年,3万张照片美伦美奂 :大数据分析图解:2019中国企业500强 张梦然:英国惠康桑格研究所:人体内的微生物与出生方式有关 :美众议院将调查华裔部长赵小兰“利用职权为家族谋利“ :UCLA CCS 2019 Fall Quarter Lecture Series Overview 谭晶晶:美国科技界高度关注中国科技创新进展
注意: 留言内容不要超过4000字,否则会被截断。
未 审 核:  是
Copyright © 2023 ScholarsUpdate.com. All Rights Reserved.